Boston Scientific Corp
NYSE:BSX

Watchlist Manager
Boston Scientific Corp Logo
Boston Scientific Corp
NYSE:BSX
Watchlist
Price: 90 USD -1.64% Market Closed
Market Cap: 132.6B USD
Have any thoughts about
Boston Scientific Corp?
Write Note

Net Margin
Boston Scientific Corp

11.3%
Current
8%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
11.3%
=
Net Income
1.8B
/
Revenue
15.9B

Net Margin Across Competitors

Country US
Market Cap 132.6B USD
Net Margin
11%
Country US
Market Cap 204.9B USD
Net Margin
14%
Country US
Market Cap 195.2B USD
Net Margin
29%
Country US
Market Cap 146.7B USD
Net Margin
16%
Country IE
Market Cap 110.6B USD
Net Margin
12%
Country US
Market Cap 64.7B USD
Net Margin
9%
Country DE
Market Cap 55.6B EUR
Net Margin
8%
Country CN
Market Cap 319.2B CNY
Net Margin
34%
Country US
Market Cap 41.6B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
Country US
Market Cap 35.8B USD
Net Margin
23%
No Stocks Found

Boston Scientific Corp
Glance View

Market Cap
132.6B USD
Industry
Health Care

Boston Scientific Corp., a global leader in medical devices, has carved out an impressive niche at the intersection of healthcare innovation and patient care. Founded in 1979, the company has since grown into a powerhouse with a diverse portfolio that includes products for cardiology, rhythm management, endoscopy, urology, and more. With a commitment to advancing science and improving lives, Boston Scientific is dedicated to developing cutting-edge technologies that address some of the most pressing challenges in medicine today. This commitment is paired with a strong focus on value creation, making the company's long-term strategy particularly appealing to investors looking for stable growth in the healthcare sector. As a publicly traded company on the New York Stock Exchange under the ticker symbol BSX, Boston Scientific has demonstrated resilience and adaptability, with consistent revenue growth driven by innovation and strategic acquisitions. The company's R&D investments are supported by a robust pipeline of new products and therapies, which promise to enhance therapeutic options and improve patient outcomes. For investors, Boston Scientific represents not just an opportunity to participate in a thriving industry with strong demand fundamentals, but also a chance to align with a firm that embodies the principles of prudent financial management and value creation akin to the teachings of Warren Buffett and Charlie Munger. With a proactive approach to market trends and a commitment to sustainability, Boston Scientific is well-positioned to navigate the evolving healthcare landscape, making it a compelling choice for investors seeking exposure to the lucrative medical devices arena.

BSX Intrinsic Value
62.59 USD
Overvaluation 30%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
11.3%
=
Net Income
1.8B
/
Revenue
15.9B
What is the Net Margin of Boston Scientific Corp?

Based on Boston Scientific Corp's most recent financial statements, the company has Net Margin of 11.3%.